Literature DB >> 19647325

The difficult-to-treat electroconvulsive therapy patient - Strategies for augmenting outcomes.

Colleen K Loo1, Andrew Kaill, Pauline Paton, Brett Simpson.   

Abstract

BACKGROUND: Several treatment strategies for augmenting outcomes with ECT (concurrent antidepressant treatment, frequency of ECT treatments, hyperventilation and use of remifentanil) are discussed in the context of a difficult clinical case, accompanied by a review of the relevant existing literature.
METHODS: Literature on the above aspects of ECT technique was identified via a PubMed search and was critically reviewed.
RESULTS: There is preliminary evidence that concurrent administration of some antidepressant medications may be useful in the highly treatment resistant patient, though due attention should be given to potential risks in combining these with ECT; reduction of the treatment frequency to twice a week; hyperventilation prior to each treatment; and the use of remifentanil to minimise the dosage of induction anaesthetics with anticonvulsant properties, may be useful strategies to enhance seizure production in cases where a high or rapidly rising seizure threshold is a major impediment to ECT treatment. LIMITATIONS: It should be noted that empirical evidence for the effectiveness of each of the above strategies in producing better outcomes with ECT is not definitive, pointing to the need for further research in these areas.
CONCLUSIONS: The above strategies may be useful in clinical ECT practice, particularly in patients who are apparently treatment resistant, but the practitioner should be aware that the level of evidence underpinning these approaches is at present, preliminary. Crown Copyright 2009. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647325     DOI: 10.1016/j.jad.2009.07.011

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  8 in total

Review 1.  Somatic treatments for mood disorders.

Authors:  Moacyr A Rosa; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2011-10-05       Impact factor: 7.853

2.  Seizure threshold increases can be predicted by EEG quality in right unilateral ultrabrief ECT.

Authors:  Verònica Gálvez; Dusan Hadzi-Pavlovic; Susan Waite; Colleen K Loo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-11       Impact factor: 5.270

3.  A review of ultrabrief pulse width electroconvulsive therapy.

Authors:  Colleen K Loo; Natalie Katalinic; Donel Martin; Isaac Schweitzer
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

4.  A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development.

Authors:  Laura Kranaster; Suna Su Aksay; Jan Malte Bumb; Carolin Hoyer; Christine Jennen-Steinmetz; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-06       Impact factor: 5.270

5.  Electroconvulsive therapy can benefit from controlled hyperventilation using a laryngeal mask.

Authors:  Martina Haeck; Benjamin Gillmann; Hildegard Janouschek; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-28       Impact factor: 5.270

6.  Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study.

Authors:  Laura Kranaster; Jutta Kammerer-Ciernioch; Carolin Hoyer; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-13       Impact factor: 5.270

7.  Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.

Authors:  Chadi G Abdallah; Madonna Fasula; Ben Kelmendi; Gerard Sanacora; Robert Ostroff
Journal:  J ECT       Date:  2012-09       Impact factor: 3.635

8.  Changes in seizure duration during acute course electroconvulsive therapy.

Authors:  James Luccarelli; Thomas H McCoy; Stephen J Seiner; Michael E Henry
Journal:  Brain Stimul       Date:  2021-06-11       Impact factor: 9.184

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.